BridgeBio Pharma Presents Updated Data From Its BBP-812 Canavan Disease Gene Therapy Program At The 51st Annual Meeting Of The Child Neurology Society
- Robust post-dosing changes continue to be seen in key markers associated with severity of disease
- Pharmacodynamic data from the first three participants show sustained reductions in N-acetylaspartate (NAA) in